Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Trial of Total Marrow and Lymphoid Irradiation (TMLI) as Conditioning for Allogeneic Peripheral Blood Stem Cell Hematopoietic Cell Transplantation (PBSC-HCT) From a Match Donor With Fludarabine and Melphalan in Older Patients With Refractory Acute Myeloid Leukemia and MDS

NCT07582172 is registered in ClinicalTrials.gov with City of Hope Medical Center as lead sponsor.

NCT NCT07582172
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07582172 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Trial of Total Marrow and Lymphoid Irradiation (TMLI) as Conditioning for Allogeneic Peripheral Blood Stem Cell Hematopoietic Cell Transplantation (PBSC-HCT) From a Match Donor With Fludarabine and Melphalan in Older Patients With Refractory Acute Myeloid Leukemia and MDS
Lead sponsor
City of Hope Medical Center
Phase
Phase 2
Overall status
Recruiting
Start date
November 5, 2026
Completion date
November 5, 2031
Enrollment
35 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia with complex karyotype, myelodysplastic chronic myelomonocytic leukemia, myelodysplastic syndrome, recurrent acute myeloid leukemia, recurrent myelodysplastic chronic myelomonocytic leukemia, recurrent myelodysplastic syndrome, recurrent secondary acute myeloid leukemia, refractory acute myeloid leukemia, refractory myelodysplastic chronic myelomonocytic leukemia, refractory myelodysplastic syndrome, refractory secondary acute myeloid leukemia